Search research articles
Contact Us
Filters
Showing results (131-140 of 163) with videos related to
Page
of 17
Sort By:
Medicine and Science in Sports and Exercise
|
April 3, 2001
Low-volume circuit versus high-volume periodized resistance training in women
J O Marx, N A Ratamess, B C Nindl, et al.
JCI Insight
|
January 19, 2023
Effect of mechanical unloading on genome-wide DNA methylation profile of the failing human heart
Xianghai Liao, Peter J Kennel, Bohao Liu, et al.
Nature Cardiovascular Research
|
June 6, 2022
Fibroblast growth factor homologous factors serve as a molecular rheostat in tuning arrhythmogenic cardiac late sodium current
Nourdine Chakouri, Sharen Rivas, Daniel Roybal, et al.
Journal of the American College of Cardiology
|
November 5, 2017
3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial
Dean J Kereiakes, Stephen G Ellis, Christopher Metzger, et al.
JCI Insight
|
April 26, 2019
Heterogeneity of the action potential duration is required for sustained atrial fibrillation
Uma Mahesh R Avula, Jeffrey Abrams, Alexander Katchman, et al.
The New England Journal of Medicine
|
October 13, 2015
Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease
Stephen G Ellis, Dean J Kereiakes, D Christopher Metzger, et al.
Canadian Journal of Applied Physiology = Revue Canadienne De Physiologie Appliquee
|
May 18, 2000
Effects of exercise and alkalosis on serum insulin-like growth factor I and IGF-binding protein-3
W J Kraemer, F S Harman, N H Vos, et al.
JCI Insight
|
September 2, 2020
Fibroblast growth factor homologous factors tune arrhythmogenic late NaV1.5 current in calmodulin binding-deficient channels
Jeffrey Abrams, Daniel Roybal, Nourdine Chakouri, et al.
Circulation
|
September 26, 2019
Clinical Outcomes Before and After Complete Everolimus-Eluting Bioresorbable Scaffold Resorption: Five-Year Follow-Up From the ABSORB III Trial
Dean J Kereiakes, Stephen G Ellis, D Christopher Metzger, et al.
Lancet (London, England)
|
September 30, 2018
Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial
Gregg W Stone, Stephen G Ellis, Tommaso Gori, et al.
Page
of 17
Search research articles
Search
Showing results (131-140 of 163) with videos related to
Sort By:
Page
of 17
Medicine and Science in Sports and Exercise
|
April 3, 2001
Low-volume circuit versus high-volume periodized resistance training in women
J O Marx, N A Ratamess, B C Nindl, et al.
JCI Insight
|
January 19, 2023
Effect of mechanical unloading on genome-wide DNA methylation profile of the failing human heart
Xianghai Liao, Peter J Kennel, Bohao Liu, et al.
Nature Cardiovascular Research
|
June 6, 2022
Fibroblast growth factor homologous factors serve as a molecular rheostat in tuning arrhythmogenic cardiac late sodium current
Nourdine Chakouri, Sharen Rivas, Daniel Roybal, et al.
Journal of the American College of Cardiology
|
November 5, 2017
3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial
Dean J Kereiakes, Stephen G Ellis, Christopher Metzger, et al.
JCI Insight
|
April 26, 2019
Heterogeneity of the action potential duration is required for sustained atrial fibrillation
Uma Mahesh R Avula, Jeffrey Abrams, Alexander Katchman, et al.
The New England Journal of Medicine
|
October 13, 2015
Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease
Stephen G Ellis, Dean J Kereiakes, D Christopher Metzger, et al.
Canadian Journal of Applied Physiology = Revue Canadienne De Physiologie Appliquee
|
May 18, 2000
Effects of exercise and alkalosis on serum insulin-like growth factor I and IGF-binding protein-3
W J Kraemer, F S Harman, N H Vos, et al.
JCI Insight
|
September 2, 2020
Fibroblast growth factor homologous factors tune arrhythmogenic late NaV1.5 current in calmodulin binding-deficient channels
Jeffrey Abrams, Daniel Roybal, Nourdine Chakouri, et al.
Circulation
|
September 26, 2019
Clinical Outcomes Before and After Complete Everolimus-Eluting Bioresorbable Scaffold Resorption: Five-Year Follow-Up From the ABSORB III Trial
Dean J Kereiakes, Stephen G Ellis, D Christopher Metzger, et al.
Lancet (London, England)
|
September 30, 2018
Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial
Gregg W Stone, Stephen G Ellis, Tommaso Gori, et al.
Page
of 17